×
About 6,382 results

ALLMedicine™ Ocular Hypertension Center

Research & Reviews  2,819 results

Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patient...
https://doi.org/10.1007/s12325-021-01634-9 10.1001/jama.2014.3192 10.1016/j.ophtha.2014.05.013 10.1016/j.ophtha.2005.05.012 10.1001/archophthalmol.2008.593 10.1016/S0002-9394(00)00538-9 10.1016/S0140-6736(04)16257-0 10.1097/ICU.0b013e32834ff23e 10.1097/00055735-200404000-00011 10.1001/archopht.120.10.1268 10.1001/archopht.120.6.701 10.1001/archophthalmol.2010.20 10.1016/S0002-9394(98)00272-4 10.1016/j.coph.2012.09.012 10.1177/2040622313511286 10.2147/OPTH.S15971 10.1089/jop.2013.0197 10.1167/iovs.05-1617 10.1097/IJG.0b013e3182952213 10.1016/j.exer.2016.08.023 10.1111/aos.12829 10.1097/IJG.0000000000001203 10.1016/j.ophtha.2009.06.024 10.1016/j.ejphar.2016.04.002 10.1089/jop.2017.0023 10.1167/iovs.16-20189 10.1089/jop.2017.0138 10.1089/jop.2014.0146 10.1007/s40265-018-0877-7 10.1016/j.ajo.2019.01.003 10.1016/j.ajo.2019.03.002 10.1016/j.ajo.2017.11.019 10.1016/j.ophtha.2014.08.022 10.1001/archopht.124.9.1230 10.1016/j.ajo.2013.05.016 10.1007/s10384-011-0048-9 10.1097/IJG.0000000000001634 10.1016/S0002-9394(02)01980-3 10.1016/S0039-6257(97)00118-5 10.1097/01.icu.0000143688.45232.15
Advances in Therapy; Araie M, Sugiyama K et. al.

Feb 25th, 2021 - Netarsudil reduces intraocular pressure (IOP) by increasing aqueous outflow through the trabecular meshwork (TM) pathway and decreasing episcleral venous pressure. The primary objective of this phase 2 study was to evaluate ocular hypotensive effi...

Qualitative Evaluation of the 10-2 and 24-2 Visual Field Tests for Detecting Central Vi...
https://doi.org/10.1016/j.ajo.2021.02.015
American Journal of Ophthalmology; Orbach A, Ang GS et. al.

Feb 24th, 2021 - To examine whether glaucomatous central visual field abnormalities can be more effectively detected using a qualitative, expert evaluation of the 10-2 test compared to the topographically corresponding central 12 locations of the 24-2 test (C24-2)...

NCX 1741, a Novel Nitric Oxide-Donating Phosphodiesterase-5 Inhibitor, Exerts Rapid and...
https://doi.org/10.1089/jop.2020.0126
Journal of Ocular Pharmacology and Therapeutics : the Off... Bastia E, Toris C et. al.

Feb 17th, 2021 - Purpose: We studied the IOP-lowering effects of NCX 1741, a novel nitric oxide (NO)-donating derivative of the phosphodiesterase type-5 inhibitor, avanafil, in Cynomolgus monkey with laser-induced ocular hypertension (OHT-monkeys). NCX 1193 (NO-do...

Pulsating Cilioretinal Artery From Ocular Hypertension.
https://doi.org/10.1001/jamaophthalmol.2020.4108
JAMA Ophthalmology; Liu Y, Chan MF et. al.

Feb 17th, 2021 - Pulsating Cilioretinal Artery From Ocular Hypertension.|2021|Liu Y,Chan MF,Stewart JM,|

How Do Patients Feel About Visual Field Testing? Analysis of Subjective Perception of S...
https://doi.org/10.1080/08820538.2021.1884270
Seminars in Ophthalmology; Mendieta N, Suárez J et. al.

Feb 15th, 2021 - A high rate of unreliability is an issue in visual field (VF) testing, especially in elderly patients, and warrants patient education. We assessed whether subjective perception of the visual field test (VFT) is a good predictor of its reliability ...

see more →

Drugs  287 results see all →

Clinicaltrials.gov  3,193 results

Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patient...
https://doi.org/10.1007/s12325-021-01634-9 10.1001/jama.2014.3192 10.1016/j.ophtha.2014.05.013 10.1016/j.ophtha.2005.05.012 10.1001/archophthalmol.2008.593 10.1016/S0002-9394(00)00538-9 10.1016/S0140-6736(04)16257-0 10.1097/ICU.0b013e32834ff23e 10.1097/00055735-200404000-00011 10.1001/archopht.120.10.1268 10.1001/archopht.120.6.701 10.1001/archophthalmol.2010.20 10.1016/S0002-9394(98)00272-4 10.1016/j.coph.2012.09.012 10.1177/2040622313511286 10.2147/OPTH.S15971 10.1089/jop.2013.0197 10.1167/iovs.05-1617 10.1097/IJG.0b013e3182952213 10.1016/j.exer.2016.08.023 10.1111/aos.12829 10.1097/IJG.0000000000001203 10.1016/j.ophtha.2009.06.024 10.1016/j.ejphar.2016.04.002 10.1089/jop.2017.0023 10.1167/iovs.16-20189 10.1089/jop.2017.0138 10.1089/jop.2014.0146 10.1007/s40265-018-0877-7 10.1016/j.ajo.2019.01.003 10.1016/j.ajo.2019.03.002 10.1016/j.ajo.2017.11.019 10.1016/j.ophtha.2014.08.022 10.1001/archopht.124.9.1230 10.1016/j.ajo.2013.05.016 10.1007/s10384-011-0048-9 10.1097/IJG.0000000000001634 10.1016/S0002-9394(02)01980-3 10.1016/S0039-6257(97)00118-5 10.1097/01.icu.0000143688.45232.15
Advances in Therapy; Araie M, Sugiyama K et. al.

Feb 25th, 2021 - Netarsudil reduces intraocular pressure (IOP) by increasing aqueous outflow through the trabecular meshwork (TM) pathway and decreasing episcleral venous pressure. The primary objective of this phase 2 study was to evaluate ocular hypotensive effi...

Qualitative Evaluation of the 10-2 and 24-2 Visual Field Tests for Detecting Central Vi...
https://doi.org/10.1016/j.ajo.2021.02.015
American Journal of Ophthalmology; Orbach A, Ang GS et. al.

Feb 24th, 2021 - To examine whether glaucomatous central visual field abnormalities can be more effectively detected using a qualitative, expert evaluation of the 10-2 test compared to the topographically corresponding central 12 locations of the 24-2 test (C24-2)...

Brimonidine - brimonidine tartrate solution/ drops-A-S Medication Solutions
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=93c1eeb2-98f8-47dd-b764-13c635e25428

Feb 21st, 2021 - Brimonidine tartrate ophthalmic solution 0.2% is indicated for lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The IOP lowering efficacy of brimonidine tartrate ophthalmic solution diminishes over t...

NCX 1741, a Novel Nitric Oxide-Donating Phosphodiesterase-5 Inhibitor, Exerts Rapid and...
https://doi.org/10.1089/jop.2020.0126
Journal of Ocular Pharmacology and Therapeutics : the Off... Bastia E, Toris C et. al.

Feb 17th, 2021 - Purpose: We studied the IOP-lowering effects of NCX 1741, a novel nitric oxide (NO)-donating derivative of the phosphodiesterase type-5 inhibitor, avanafil, in Cynomolgus monkey with laser-induced ocular hypertension (OHT-monkeys). NCX 1193 (NO-do...

Pulsating Cilioretinal Artery From Ocular Hypertension.
https://doi.org/10.1001/jamaophthalmol.2020.4108
JAMA Ophthalmology; Liu Y, Chan MF et. al.

Feb 17th, 2021 - Pulsating Cilioretinal Artery From Ocular Hypertension.|2021|Liu Y,Chan MF,Stewart JM,|

see more →

News  83 results

Selective Laser Trabeculoplasty's Value Rises During COVID-19
https://www.medscape.com/viewarticle/941990

Dec 8th, 2020 - With the ongoing pandemic, ophthalmologists continue to search for new ways to reduce patient visits and possible virus exposure without sacrificing outcomes. Not surprisingly, monitoring and adjusting eye drop treatments to lower intraocular pres...

EMA Panel Backs Roclanda Eyedrops, New Option for Glaucoma
https://www.medscape.com/viewarticle/941062

Nov 15th, 2020 - The European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the fixed-dose combination of latanoprost and netarsudil (Roclanda). The ophthalmic solution is indicated to decrease elevate...

Consider Medication Washout for Some Glaucoma Patients
https://www.staging.medscape.com/viewarticle/929567

Apr 28th, 2020 - NEW YORK (Reuters Health) - Patients with uveitic glaucoma (UG) whose intraocular pressure (IOP) is under control and do not have uveitis recurrence may benefit from ocular hypotensive treatment washout, new findings show. Stopping hypotensive tre...

Consider Medication Washout for Some Glaucoma Patients
https://www.medscape.com/viewarticle/929567

Apr 28th, 2020 - NEW YORK (Reuters Health) - Patients with uveitic glaucoma (UG) whose intraocular pressure (IOP) is under control and do not have uveitis recurrence may benefit from ocular hypotensive treatment washout, new findings show. Stopping hypotensive tre...

FDA OKs First Biodegradable Implant to Lower Intraocular Pressure
https://www.staging.medscape.com/viewarticle/926325

Mar 4th, 2020 - The US Food and Drug Administration (FDA) has approved Allergan's bimatoprost implant (Durysta), the first intracameral biodegradable sustained-release implant designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma (OAG)...

see more →